| |
Move beyond a single set of forecast numbers and embrace uncertainty in healthcare forecasting: IQVIA’s Forecast Horizon is enabling pharma to broaden their analysis and drive deeper insights. Learn more. 
|
|
| By Paige Minemyer Just weeks after securing a federal court win allowing their merger to go forward, UnitedHealth Group has completed its controversial acquisition of Change Healthcare. |
|
|
|
By Kevin Dunleavy In going all the way to the U.S. Supreme Court in a bid to reinstate the patent of blockbuster drug Tecfidera, Biogen was throwing a desperation Hail Mary. On Monday morning, the attempt was swatted away as the court decided not to hear the case |
By Nick Paul Taylor AstraZeneca has identified a shortcut to prominence in the genomic medicine space. Working through its Alexion rare disease unit, the Big Pharma has struck a deal to snap up struggling LogicBio Therapeutics to secure technology platforms and expertise in their use. |
By Conor Hale Researchers at the university have developed a motorized pill with a spinning, augerlike end piece designed to displace the mucus and deliver its payload directly to the organ. |
By Paige Minemyer Medicare's annual enrollment period opens soon, and major insurers are making the pitch now to potential members in the coming year. |
By Angus Liu Clovis Oncology is already fighting the FDA over expanding Rubraca into an earlier treatment line in ovarian cancer. Now, the company hopes the U.S. regulator could allow the troubled PARP inhibitor a similar move in prostate cancer—but the situation is complicated. |
By Nick Paul Taylor Johnson & Johnson has posted clinical data on its $100 million gene therapy bet. The Big Pharma linked its inherited retinal disease candidate to improved vision in a phase 1/2 clinical trial, offering insights into how it may perform in an ongoing pivotal study. |
By Conor Hale Catapult will propel the Tasso+ blood collector into people's homes as part of its VirtualCheckup program. |
By Fraiser Kansteiner Kite's viral vector plant in Southern California has been cleared for liftoff, and, with that, the Gilead company is touting its position as the only cell therapy player able to make in-house viral vectors for both its pipeline prospects and pair of commercial CAR-Ts. |
By Max Bayer More than a month after PACT Pharma said it was diverting some 50 employees to a new business development venture, the company has unveiled its plan. PACT is selling off select assets and its manufacturing facility to AmplifyBio. |
By Dave Muoio A new analysis estimates 25 coastal metros would see the majority of their hospitals hamstrung by a Category 2 hurricane or stronger. The number is only expected to increase as climate change raises sea levels. |
By Gabrielle Masson A string of recent biotech SPAC mergers in biotech could put the so-called blank check deals back on track after near-extinction. The latest is early-stage cancer therapeutics company Estrella Biopharma, which signed a deal to merge with TradeUP Acquisition. Corp. |
By Conor Hale Roche has named the next CEO for its diagnostics efforts, as its prior division chief, Thomas Schinecker, is waiting in the wings to head up the Big Pharma overall starting next March. |
Fierce podcasts Don't miss an episode |
| This week on "Podnosis," we talk about how AI is helping patients and what’s standing in the way of more widespread use. We also chat about how payers have invested in bringing on expertise necessary to tackle social determinants of health |
|
|---|
|
|
|
Monday, October 17, 2022 | 11am ET / 8am PT Join the Omic Revolution! Register now to attend a FREE webinar to leverage deep multiomic data integration for target and biomarker discovery. 
|
|
eBook With real-world data playing a significant role in health care decisions, life sciences leaders need to maximize their data investments. The best place to start is right here, with our e-book on the four steps to a more coordinated, connected real-world data strategy. Sponsored by: Optum |
Whitepaper Learn the benefits of unlocking data insights across the healthcare and life sciences ecosystem. Sponsored by: NTT Data |
Whitepaper Read about key factors and trends in RWE and how our data luminaries are the right partner to lead the way forward. Sponsored by: Lumanity |
Whitepaper SaaS LIMS from LabVantage Solutions Is Pre-Validated for Regulated Industries, Delivering Maximum Flexibility, Uptime, and Security. Sponsored by: LabVantage Solutions Inc. |
Whitepaper This paper is the first in a 4-part series focused on developing commercial models for gene therapies Sponsored by: Blue Matter, strategic consultants in the life sciences |
eBook Improve your congress competitive intelligence and cut down costs by 50% Sponsored by: Ferma.AI, a Product of ZoomRx |
Whitepaper Supporting your product development programme through experience, expertise, and efficiency. Sponsored by: Almac Pharma Services |
Whitepaper Advanced research requires advanced tools. The next-generation ELISA takes a fraction of the time to run eight analytes simultaneously while saving your sample volume. Sponsored by: Bio-Techne |
eBook Improve patient engagement, adherence, and outcomes Sponsored by: Health Catalyst |
Video Can an optimized research process--including AI-powered workflow and process automation tools--help get breakthrough drugs to market faster? Sponsored by: Proscia |
Video Learn how a centralized platform for pathology images, metadata, and analysis results can connect previously siloed research initiatives and advance our collective understanding of tissue. Sponsored by: Proscia |
Whitepaper What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Catalent |
Research Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent |
Whitepaper How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent |
Whitepaper Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Biologics |
Webinar Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. Sponsored by: Catalent Biologics |
Custom Resource Center Read through this library of resources to find out how you can strengthen innovation and efficiency, improve safety and quality, and prioritize resources to support your long-term goals. Sponsored by: JLL |
Whitepaper Clarus Therapeutics (Clarus) is a men’s specialty pharmaceutical company that partnered with Catalent to develop a unique and convenient drug delivery form for their hormone replacement therapy. Sponsored by: Catalent |
Whitepaper Learn more about how the transition from early to late phase of a small molecule program plays a pivotal role in a program’s ultimate success. Sponsored by: Catalent |
Whitepaper Explore how Thermo Scientific’s Process Liquid Preparation Services can help you plan for scalable buffer preparation. Sponsored by: Thermo Fisher Scientific |
eBook Orally Inhaled & Nasal Drug Delivery: A Pipeline of Opportunities Sponsored by: Catalent |
Whitepaper Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored by: Catalent |
Whitepaper What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored by: Catalent |
| |
|
